Data presented at the European Association for the Study of Diabetes meeting revealed a fixed-dose insulin degludec/liraglutide combination resulted in greater blood glucose control in type 2 diabetes patients compared with either monotherapy. The insulin degludec/liraglutide combination treatment resulted in a greater proportion of subjects with blood glucose values within …

Dulaglutide (Trulicity) is approved as a once-weekly injection for the treatment of type 2 diabetes…. Dulaglutide is a member of the glucagon-like peptide (GLP-1) receptor agonist class, along with liraglutide, exenatide, and albiglutide. The US Food and Drug Administration (FDA) has approved dulaglutide (Trulicity) as a once a week injection …

A large study in the UK looked at the long-term effects of GLP-1 and DPP-4 therapy on patients’ risk of congestive heart failure….

Using a GLP-1 agonist with insulin may be the most effective therapy combination for lowering HbA1c in type 2 diabetes patients…. Researchers performed a systematic review and pooled meta-analysis of randomized controlled trials published between January 1, 1950 and July 29, 2014. Out of the 2,905 studies that were identified, …

Low HDL increases the risk of heart disease but does it also increase the risk of cancer?…

Nitric oxide helped modulate hepatic lipid metabolism in addition to decreasing insulin clearance in a study….

The U.S. Food and Drug Administration has approved the use of Eylea (aflibercept) which may improve vision for patients with diabetes….

Eating a lot of higher fat dairy products seemed to lower the risk of type 2 diabetes development by up to 23%…. 

Tresiba, in combination with insulin aspart, effectively improved long-term glycemic control….

IL-13, a cytokine produced by activated Th-2 lymphocytes, is involved in several stages of beta cell maturation and differentiation….